SNG-M Xenograft Model Service for Endometrial Cancer

The SNG-M xenograft model offers a validated preclinical platform for endometrial carcinoma research, enabling robust evaluation of therapeutic efficacy and tumor biology in an immunodeficient host environment. Alfa Cytology provides comprehensive, GLP-compliant SNG-M xenograft model services tailored to support your oncology drug discovery programs---from initial pharmacokinetic profiling through to advanced efficacy and biomarker endpoint analysis.

Overview of SNG-M Xenograft Model for Endometrial Cancer

The SNG-M cell line was established from a metastatic lymph node of a human endometrial adenocarcinoma patient and is classified as an intermediately differentiated adenocarcinoma line (JCRB0179 / IFO50313). It has been extensively utilized in immunotherapy and hypoxia-response studies, demonstrating measurable susceptibility to lymphokine-activated killer (LAK) cell-mediated lysis in vitro and in vivo. When implanted into immunodeficient nude mice, SNG-M forms xenograft tumors that retain histopathological features consistent with endometrial adenocarcinoma, providing a reproducible system for preclinical pharmacological evaluation.

SNG-M exhibits active hypoxia-inducible factor (HIF-1alpha) signaling under low-oxygen conditions, with differential expression of downstream targets such as VEGF, SLC2A1, and DEC2. This molecular profile makes the SNG-M xenograft particularly relevant for studying anti-angiogenic agents, hypoxia-activated prodrugs, and metabolic modulators in endometrial cancer. The model supports both subcutaneous and orthotopic implantation routes, enabling flexible study designs that span tumor growth inhibition, survival analysis, and biomarker-driven pharmacodynamic assessment.

Figure 1. The functions of USP14 in mediating the apoptosis, migration and invasion of EC cells. (Gong, Xiaojin, et al., 2023)

Cell Line Information: SNG-M

SNG-M is a well-characterized human endometrial adenocarcinoma cell line derived from a metastatic lesion. The table below summarizes its essential characteristics.

Our Services

Alfa Cytology leverages the SNG-M cell line to deliver standardized, high-quality xenograft models with rigorous quality control at every stage---from cell line authentication and mycoplasma screening to in vivo tumor monitoring and endpoint histopathology. Our scientific team ensures that each study is designed to meet your specific pharmacological objectives, providing reliable data to advance your endometrial cancer therapeutic pipeline.

Workflow of SNG-M Xenograft Model Construction

The construction of the SNG-M xenograft model follows a standardized, quality-controlled pipeline that ensures reproducible tumor growth and reliable pharmacological readouts. The process begins with authenticated cell stock preparation and progresses through host selection, tumor implantation, randomization, and comprehensive endpoint analysis.

1. Cell Line Authentication and Expansion: SNG-M cells are revived from authenticated cryopreserved stocks (JCRB0179) and expanded under standardized culture conditions. Each batch undergoes STR profiling for identity confirmation and mycoplasma testing to ensure contamination-free inoculum.
2. Host Selection and Preparation: Immunodeficient mice (typically female BALB/c nude or NOD-SCID) aged 6-8 weeks are acclimatized under pathogen-free conditions. Animal health status is verified prior to enrollment to minimize inter-animal variability.
3. Tumor Cell Inoculation: Exponentially growing SNG-M cells are harvested, washed, and resuspended in a 1:1 mixture of serum-free medium and Matrigel at a density of 5x10^6 to 1x10^7 cells per 100-200 microL. The cell suspension is injected subcutaneously into the flank or orthotopically into the uterine horn depending on study design.
4. Tumor Engraftment Monitoring: Tumor formation is monitored by palpation and electronic caliper measurement beginning 3-5 days post-inoculation. Tumor volume is calculated using the modified ellipsoid formula (V = 0.5 x length x width^2). Mice are randomized into treatment cohorts once tumors reach 100-150 mm^3.
5. Drug Administration and In-Life Observations: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weight, tumor dimensions, and clinical signs are recorded at defined intervals throughout the treatment period.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), biomarker analysis (Western blot, qPCR), and pharmacokinetic profiling. Blood samples and major organs are collected for toxicity assessment as required.

Figure 2: Schematic workflow illustrating the derivation and construction of the SNG-M Xenograft Model at Alfa Cytology.

Case Study-SNG-M Xenograft Model Development

In a representative pharmacological study, SNG-M xenografts were established in female BALB/c nude mice to evaluate the efficacy of a novel anti-angiogenic compound. Following tumor engraftment and randomization, mice received the test agent or vehicle control over a 21-day treatment window. The study demonstrated dose-dependent tumor growth inhibition, with treated cohorts showing significant reductions in tumor volume and weight compared to control groups. Pharmacodynamic analysis revealed downregulation of tumor VEGF expression and decreased microvessel density, consistent with the compound's proposed mechanism of action. These results illustrate the utility of the SNG-M model in generating actionable preclinical data for endometrial cancer drug candidates. [Specific data points available upon request for customization.]

Why Choose Alfa Cytology?

Alfa Cytology is a specialized contract research organization dedicated exclusively to preclinical tumor model services. Our SNG-M xenograft program combines scientific rigor with operational flexibility to accelerate your endometrial cancer therapeutic development.

• Authenticated cell lines with documented STR profiles and regular mycoplasma screening to ensure model integrity.
• Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations.
• Comprehensive endpoint capabilities spanning tumor growth kinetics, survival analysis, histopathology, and biomarker quantification.
• Experienced oncology study directors with deep expertise in endometrial carcinoma biology and xenograft pharmacology.
• Rapid study initiation with dedicated project management and transparent milestone reporting.
• Competitive pricing without compromising GLP-compliant documentation and data quality standards.

Contact Us

Partner with Alfa Cytology to advance your endometrial cancer research with our validated SNG-M xenograft model. Whether you require a standard tumor growth inhibition study or a complex biomarker-driven pharmacodynamic assessment, our team is ready to design and execute a protocol that meets your exact specifications. Please reach out to us today via our inquiry form or email to learn more about our SNG-M Xenograft Model services.

For research use only. Not intended for any clinical use.